These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
570 related articles for article (PubMed ID: 25750267)
21. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. Stovgaard ES; Nielsen D; Hogdall E; Balslev E Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430 [TBL] [Abstract][Full Text] [Related]
22. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. Edwards DN; Ngwa VM; Raybuck AL; Wang S; Hwang Y; Kim LC; Cho SH; Paik Y; Wang Q; Zhang S; Manning HC; Rathmell JC; Cook RS; Boothby MR; Chen J J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33320840 [TBL] [Abstract][Full Text] [Related]
23. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Disis ML; Stanton SE Am Soc Clin Oncol Educ Book; 2015; ():e25-30. PubMed ID: 25993181 [TBL] [Abstract][Full Text] [Related]
24. Identification of dysregulated microRNAs in triple-negative breast cancer (review). Yang F; Zhang W; Shen Y; Guan X Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912 [TBL] [Abstract][Full Text] [Related]
25. Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Araujo JM; Gomez AC; Aguilar A; Salgado R; Balko JM; Bravo L; Doimi F; Bretel D; Morante Z; Flores C; Gomez HL; Pinto JA Sci Rep; 2018 Mar; 8(1):4899. PubMed ID: 29559701 [TBL] [Abstract][Full Text] [Related]
26. The potential role of CD8+ cytotoxic T lymphocytes and one branch connected with tissue-resident memory in non-luminal breast cancer. Zhao Z; Ma X; Cai Z PeerJ; 2024; 12():e17667. PubMed ID: 39006029 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in triple-negative breast cancer. Katz H; Alsharedi M Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938 [TBL] [Abstract][Full Text] [Related]
28. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384 [TBL] [Abstract][Full Text] [Related]
29. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. Safarpour D; Tavassoli FA Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144 [TBL] [Abstract][Full Text] [Related]
30. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Michaels E; Chen N; Nanda R Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617 [TBL] [Abstract][Full Text] [Related]
31. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. Park IA; Hwang SH; Song IH; Heo SH; Kim YA; Bang WS; Park HS; Lee M; Gong G; Lee HJ PLoS One; 2017; 12(8):e0182786. PubMed ID: 28817603 [TBL] [Abstract][Full Text] [Related]
32. Triple-negative breast cancer-Role of immunology: A systemic review. Oner G; Altintas S; Canturk Z; Tjalma W; Verhoeven Y; Van Berckelaer C; Berneman Z; Peeters M; Pauwels P; van Dam PA Breast J; 2020 May; 26(5):995-999. PubMed ID: 31797488 [TBL] [Abstract][Full Text] [Related]
34. Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure. Saravanan R; Balasubramanian V; Sundaram S; Dev B; Vittalraj P; Pitani RS; Shanmugasundaram G; Rayala SK; Venkatraman G J Cell Physiol; 2024 Apr; 239(4):e31203. PubMed ID: 38345361 [TBL] [Abstract][Full Text] [Related]
35. LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. Pan S; Wan M; Jin H; Ning R; Zhang J; Han X BMC Immunol; 2024 Jul; 25(1):42. PubMed ID: 38977952 [TBL] [Abstract][Full Text] [Related]
36. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417 [TBL] [Abstract][Full Text] [Related]
37. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Gruosso T; Gigoux M; Manem VSK; Bertos N; Zuo D; Perlitch I; Saleh SMI; Zhao H; Souleimanova M; Johnson RM; Monette A; Ramos VM; Hallett MT; Stagg J; Lapointe R; Omeroglu A; Meterissian S; Buisseret L; Van den Eynden G; Salgado R; Guiot MC; Haibe-Kains B; Park M J Clin Invest; 2019 Apr; 129(4):1785-1800. PubMed ID: 30753167 [TBL] [Abstract][Full Text] [Related]
38. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208 [TBL] [Abstract][Full Text] [Related]
39. Infiltration of CD8 Li X; Gruosso T; Zuo D; Omeroglu A; Meterissian S; Guiot MC; Salazar A; Park M; Levine H Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3678-3687. PubMed ID: 30733298 [TBL] [Abstract][Full Text] [Related]
40. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Forero A; Li Y; Chen D; Grizzle WE; Updike KL; Merz ND; Downs-Kelly E; Burwell TC; Vaklavas C; Buchsbaum DJ; Myers RM; LoBuglio AF; Varley KE Cancer Immunol Res; 2016 May; 4(5):390-9. PubMed ID: 26980599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]